Eric Dobmeier - 14 Jun 2021 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Reporting relationship: President, CEO, Director
Issuer ticker: N/A
Reported as of: 14 Jun 2021
Net transaction value: +$7,000
SEC form: 4
Accepted by SEC: 15 Jun 2021, 17:24:44 UTC
Prior SEC filing: 09 Jun 2021
Next SEC filing: 19 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Kirk Schumacher, Attorney-in-Fact

Key filing fact

Eric Dobmeier filed Form 4 for CHINOOK THERAPEUTICS, INC. on 15 Jun 2021.

Key facts

This page summarizes Eric Dobmeier's Form 4 filing for CHINOOK THERAPEUTICS, INC..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2021, 17:24.

Change

Previous filing in this sequence was filed on 09 Jun 2021.
Current net transaction value: +$7,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KDNY transaction

Common Stock

Options Exercise

Transaction value: $7,000
Shares: +20,000
Change %: +26%
Price: $0.3500^*
Shares after: 97,837
Date: 14 Jun 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KDNY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -20,000
Change %: -4.5%
Price: $0.000000
Shares after: 423,358
Date: 14 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $0.3500
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vested as to 25% of the total shares on April 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.